Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...

3 days ago · Ozempic ® is now indicated to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease ; The ...

Apr 2, 2024 · In 2023, a clinical trial called Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) showed that Wegovy can significantly reduce the risk of major heart events—this time in people with extra weight and a cardiovascular condition who don’t have diabetes.

Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events (MACE; defined as CV death, non-fatal stroke, non-fatal myocardial infarction) with semaglutide than with placebo (hazard ratio [95% CI]: 0.74 [0.58;0.95] for once-weekly s.c. semaglutide and 0.79 [0.57;1.11...

Nov 16, 2023 · New research presented at the American Heart Association Scientific Sessions indicates that semaglutide, the active ingredient in Ozempic and Wegovy, has significant effects on heart health....

Learn more about the cardiovascular benefit of Ozempic® (semaglutide) injection and prescribing to your adult patients with T2D and established CVD. Read Important Safety and Prescribing Information, including Boxed Warning.

Oct 3, 2024 · Fact number one, GLP-1 drugs (like Ozempic) can contribute to heart health in several ways. Proven benefits, such as weight loss and better glycemic control, significantly reduce cardiovascular risk. Having better control on body weight and diabetes are the key reasons for cardiovascular health improvement on GLP-1 medications.

Jan 16, 2020 · In the 2-year SUSTAIN 6 trial, Ozempic ® significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal heart attack or...

Semaglutide, the molecule found in Ozempic, Rybelsus, and Wegovy, surged into the public eye boasting impressive claims of enhanced diabetes control, weight loss, and a reduced risk of heart attacks and strokes. Novo Nordisk, the company behind semaglutide, is finding it challenging to keep up with the overwhelming demand for these medications.

Jan 21, 2020 · Rybelsus (a pill version of Ozempic) is confirmed to be safe for the heart. The FDA approved Ozempic, a once weekly injectable GLP-1 agonist medication, in December 2017 to be taken by people with type 2 diabetes.